When investigating the mechanism behind this therapeutic resistance in patients with liver involvement, we did not identify any difference in the incidence of common molecular drivers of CRC, such as BRAF, KRAS, NRAS, and HER2, in patients with liver metastasis compared to those with non-liver metastasis. Here, KRAS is linked to colorectal carcinoma.